Results

PaperS7500

Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models

Bahareh Ajami, Nikolay Samusik, Peter Wieghofer, Peggy P. Ho, Andrea Crotti, Zach Bjornson, Marco Prinz, Wendy J. Fantl, Garry P. Nolan, Lawrence Steinman. med.stanford.edu. March 5, 2018.

Ajami, Nolan and colleagues analyse brain myeloid populations in mouse disease models. Mouse treatment findings do not establish human therapy or UAP-related illness. Pooling, statistical assumptions and inconsistencies constrain interpretation.

Paper, methods, figures and checklist read
PaperS7593

Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry

Veronica D. Gonzalez, Nikolay Samusik, Tiffany J. Chen, Erica S. Savig, Nima Aghaeepour, David A. Quigley, Ying-Wen Huang, Valeria Giangarrà, Alexander D. Borowsky, Neil E. Hubbard, Shih-Yu Chen, Guojun Han, Alan Ashworth, Thomas J. Kipps, Jonathan S. Berek, Garry P. Nolan, Wendy J. Fantl. ebi.ac.uk. February 13, 2018.

Mass cytometry identifies tumor-cell subsets and outcome associations in a small ovarian-cancer cohort. Dominant and hybrid clusters did not individually correlate with relapse. Same-cohort marker selection and missing independent validation limit interpretation; cell-line response is not demonstrated patient benefit.

Supplied author manuscript read; figures and supplement missing
PaperS7558

Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy

Nitya Nair, Henrik E. Mei, Shih-Yu Chen, Matthew Hale, Garry P. Nolan, Holden T. Maecker, Mark Genovese, C. Garrison Fathman, Chan C. Whiting. ebi.ac.uk. May 18, 2015.

This 2015 review discusses mass cytometry as a possible aid to rheumatic-disease research. Its preliminary illustration compares one patient with one healthy control; concurrent treatment and assay timing limit interpretation. The authors explicitly consider residual drug neutralizing added TNF as an alternative to changed cell signaling. The illustration does not establish a validated biomarker or clinical recommendation. Nolan is a verified coauthor, while detailed individual contribution roles are not supplied.

Complete supplied review text and figures read
PaperS7579

Early reprogramming regulators identified by prospective isolation and mass cytometry

Ernesto Lujan, Eli R. Zunder, Yi Han Ng, Isabel N. Goronzy, Garry P. Nolan, Marius Wernig. ebi.ac.uk. April 1, 2015.

A mouse-cell study associates early reprogramming with a transient marker state, while showing that marker usefulness changes with time and model. Bulk colonies and unique reprogramming events are different outcomes. Limited replication, negative controls and speculative human extension remain explicit. The supplied manuscript text is read; full diagrams, tables and publisher corrections remain incomplete.

Complete supplied manuscript text read; meaningful apparatus partial
PaperS7583

SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia

Jolanda Sarno, Angela M Savino, Chiara Buracchi, Chiara Palmi, Stefania Pinto, Cristina Bugarin, Astraea Jager, Silvia Bresolin, Ruth C Barber, Daniela Silvestri, Shai Israeli, Martin JS Dyer, Giovanni Cazzaniga, Garry P Nolan, Andrea Biondi, Kara L Davis, Giuseppe Gaipa. ebi.ac.uk. May 1, 2018.

A preclinical leukemia study reports signaling and cell-viability responses to SRC/ABL inhibition. Results vary across selected samples, cell models and treatment conditions. Negative findings, limited sample availability and statistical inconsistencies qualify the claims. The supplied main text and supplement are read; clinical effectiveness and UAP relevance are not established.

Supplied main text and supplement read; original main layout incomplete

A curated public selection. Source review describes what was read; it does not establish that a claim is true. Our research approach